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Background: Microplate-based thrombin generation test (TGT) is widely used as clinical measure of global
hemostatic potential and it becomes a useful tool for control of drug potency and quality by drug manufactures.
However, the convenience of the microtiter plate technology can be deceiving: microplate assays are prone to
location-based variability in different parts of the microtiter plate.
Methods: In this report, we evaluated the well-to-well consistency of the TGT variant specifically applied to the
quantitative detection of the thrombogenic substances in the immune globulin product. We also studied the utility
of previously described microplate layout designs in the TGT experiment.
Results: Location of the sample on the microplate (location effect) contributes to the variability of TGT
measurements. Use of manual pipetting techniques and applications of the TGT to the evaluation of procoagulant
enzymatic substances are especially sensitive. The effects were not sensitive to temperature or choice of microplate
reader. Smallest location effects were observed with automated dispenser-based calibrated thrombogram
instrument. Even for an automated instrument, the use of calibration curve resulted in up to 30% bias in
thrombogenic potency assignment.
Conclusions: Use of symmetrical version of the strip-plot layout was demonstrated to help to minimize location
artifacts even under the worst-case conditions. Strip-plot layouts are required for quantitative thrombin-generation
based bioassays used in the biotechnological field.
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Thrombin generation test (TGT) measures kinetics of
thrombin activity during coagulation of a blood plasma
sample mixed with activators of blood coagulation [1].
The TGT is widely used in clinical research to measure
global hemostatic potential in blood coagulation disor-
ders either for diagnostic purposes [2,3] or as means of
treatment monitoring [4,5]. More recently, TGT became
a useful tool in drug development and control of drug
potency and quality in drug manufacture [6-9]. Although
proposed in the 1950s [10], the test gained popularity* Correspondence: mikhail.ovanesov@fda.hhs.gov
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reproduction in any medium, provided the oronly a decade ago after the technique was revolutionized
with the introduction of fluorogenic thrombin substrates
and microtiter plate reader format [2]. However, the
convenience of the microtiter plate technology can be
deceiving: microtiter plate assays are prone to a special
kind of variability caused by the uneven microenviron-
ments in different wells of the plate [11].
In order to describe the location-based effects for the
TGT assay, a recent biotechnology application of TGT
was used. We and others found that the procoagulant ac-
tivity of IVIG correlates with reported myocardial infarc-
tion, stroke and other thromboembolic events [12,13].
Commercial (CAT® by Stago and Technothrombin® by
Technoclone) as well as in house variants of the
fluorogenic TGT method were especially helpful in identi-
fication of procoagulant IVIG lots by manufacturers andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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both in house and commercial methods are prone to
location-based biases which can be addressed with the use
of symmetrical strip-plot layout design.
Materials and methods
Materials
Human normal pooled plasma (FACT) was from George
King Biomedicals. Immunodepleted Factor XI deficient
plasma was from Affinity Biologicals (Ontario, Canada).
Human plasma-derived Factor XIa was from Haemato-
logic Technologies Inc (Essex Junction, VT). Recombin-
ant lipidated tissue factor (rTF, Dade Innovin) was from
Dade Behring (Marburg, Germany). TF activity was deter-
mined using the Actichrome TF chromogenic kit (American
Diagnostica). Fluorogenic substrate for thrombin Z-Gly-Gly-
Arg-AMC was from Bachem (Torrance, CA). Phospholipid
vesicles were from Technoclone (Diapharma, West Chester,
OH). The Thrombin Calibrator and TF reagent PPP-low
used in the CAT instrument experiment were from
Thrombinoscope BV, Maastricht, The Netherlands.
In house thrombin generation test for IVIG
procoagulant activity
Thrombin generation was measured as described in
[8,16,17]. Thrombin generation profiles in FXI-deficient
or normal plasma (75% by reaction volume) supplemented
with fluorogenic substrate Z-Gly-Gly-Arg-AMC (800 μM)
and phospholipids vesicles (4 μM) were mixed with seri-
ally diluted thrombogenic lot of IVIG or FXIa. To reduce
procedural errors, all reagents and plates were kept on
plate heater (37°C); plasma was mixed with substrate and
lipids prior transfer to microtiter wells; IVIG and FXIa
samples (20% by reaction volume) were transferred to
plasma using a 12- or 8-channel pipette, and reaction was
started by rapidly adding 2.54 μL (2.5% by reaction vol-
ume) of a mixture containing tissue factor (0.3 pM) and
CaCl2 (20 mM) using another 12-channel pipette. Record-
ing was conducted in two microplate readers, Infinite
F500 (Tecan, Durham, NC) and Synergy H4 (Biotek,
Winooski, VT) at 37°C.
TG curve processing software
In house assay data processing was performed using an
automated software package designed by Dr. Mikhail
Ovanesov using OriginPro (OriginLab, Northampton,
MA; the package is available from us upon request). The
software is capable of applying different processing algo-
rithms during the conversion of raw fluorescence to the
processed TG curve, and computes the final TG curve
parameters. The software can also apply the thrombin
calibration and thrombin-α2macroglobulin (α2MG) cor-
rection algorithms [2]. For quantitative assessment of
IVIG procoagulant activity (a bioassay approach [15]), acalibration curve was prepared from a serially diluted
IVIG standard or FXIa. Thrombin peak height (TPH)
values were plotted against FXIa concentration and fit-
ted with a cubic polynomial equation. To calculate FXIa
activity in the well, the calibration curve was applied to
the TPH and multiplied by the pre-dilution of the sam-
ple in the well.
Commercial thrombin generation test (CAT)
IVIG samples were mixed with plasma as described in
the in house method, but after that the experiment was
performed and processed according to the manufacturer’s
guidelines using CAT microplate reader and software pack-
age (Diagnostica Stago, Inc., Parsippany, NJ).
Results
Row-dependent location artifacts of TGT
In 2010 we found that lots of IVIG products implicated
in thrombotic adverse events can be evaluated with the
TGT [14,15]. Mixing normal or FXI-deficient plasma
with a thrombotic lot resulted in increased peak throm-
bin heights and shortened times to peaks [14,18]. FXI-
deficient plasma provided better resolution of low and
high procoagulant lots because almost no thrombin
generation was observed in this plasma without added
IVIG samples. To characterize the procoagulant activ-
ity of multiple IVIG products, we used thrombotic
IVIG samples as internal assay controls. To simplify
and standardize testing of hundreds of IVIG lots, con-
trols were repeated on each row in the same position
(i.e., as “row controls”), as shown in Figure 1A. This
arrangement of samples is consistent with the high-
throughput implementation of the manual TGT that
utilizes 12-channel pipette for quick recalcification of
samples in one row [8]. Consistently with the use of
the row-to-row recalcification strategy, we found some
random row-to-row variability in TPHs between and
within microplates (data not shown). These differences
could be traced back to inaccurate dispensing of TF
and calcium chloride reagent.
However, we found that TG in duplicate wells containing
the same IVIG sample can differ in a non-random
systematical manner by up to 50% if the wells are located
on separate rows of the plate. This can be illustrated by
progressively reduced and delayed TG of “row control”
samples on rows A through H (Figure 1B). Since lag time
and time to thrombin peak were affected greater than the
TPH by this systematic error, we chose TPH as the pri-
mary measure of IVIG procoagulant activity.
Analysis of multiple TGT microplate experiments
presented in Figure 1C demonstrates statistically significant
trends between upper and lower rows of the microplate
under variety of conditions. Similar trends were observed
for two IVIG samples (Figure 1C, compare black and light
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Figure 1 Row artifacts (location effects) in the TGT assay for procoagulant activity of immune globulin products. A. 96 well microplate
diagram showing location of row standards (shaded circles) included in each TGT experiment. B. Effect of row location on the thrombin
generation curve in a typical experiment. C. Effect of row location on thrombin peak height (TPH) under a variety of conditions. TPHs were
normalized on the first recalcified row (either row A or H). Means ± S.D. are shown. Black bars: n = 19 assays; FXI-deficient plasma (FXIDP) mixed
with IVIG sample #1. Order of recalcification: row A ➔ row H. Dark gray bars: n = 2; conditions as in black bars but the order of row recalcification
is reversed (row H ➔ row A). Light gray bars: n = 7; conditions as in black bars but IVIG sample #2 (higher activity) was used. White bars: n = 7;
conditions as in light gray bars but normal pooled plasma was used. Symbols above bars indicate statistically significant difference versus first
recalcified row using paired t-test (P < 0.05).
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to this trend which correlates well with lower sensitivity of
normal plasma to procoagulant activity under the condi-
tions of this experiment (data not shown). Interestingly,
when the order of row recalcification was reversed from
A ➔ H to H ➔ A, the trend was also reversed (Figure 1C,
compare black and dark gray bars).
Effect of temperature
Previous investigations demonstrated that reduced
temperature of plasma sample prior to placement of
the microplate into the reader may lead to increased
thrombin generation [19]. However, the role of temperature
in the observed row-to-row artifacts was ruled out in
our experiments. We kept our plasma and microplates
on heat plates (three different brands of heaters used)
and used pre-warmed pipet tips and microplate readers.
The temperature of plasma wells on the heater before,
after recalcification and after readings in the microplatereader was the same as assessed by an infra-red thermom-
eter (0.1°C resolution).
Row effect on IVIG samples with different
procoagulant activities
Normalization of the sample responses on the response
of internal standard control can be used to address ran-
dom and systematic errors in biological assays. However,
normalization of TG peak heights in various tested IVIG
samples on the respective “row control” presented in
Figure 1 failed to correct for row-to-row artifacts (data
not shown). Further analysis revealed that normalization
is ineffective because samples with high and low procoagu-
lant activities are affected differently by row artifact. To
model samples of different procoagulant activity, procoagu-
lant IVIG lot was serially diluted and tested repeatedly on
rows A through H (Figure 2A). On each row, the TG curves
demonstrated clear dose-response (Figure 2B). Consistent
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Data from Row B
Figure 2 Random and systemic location effects observed for serially diluted procoagulant IVIG product. A. 96 well microplate diagram
showing row-to-row location of serially diluted IVIG sample. Blue and red colors on this and other panels denote 1.6- and 16.8-fold dilutions,
respectively. B. Thrombin generation profiles in FXIDP mixed with serially diluted thrombogenic lot of IVIG. Data from row B. C. Effect of row
location on the TPH measured in the TGT assay. Note random row variations, e.g., relatively low thrombin peaks on rows B and F, and systemic
trend to TPH reduction on rows A ➔ B. D. Linear fit was used to demonstrate that row-to-row drift is dependent on the activity of the sample
and time between row recalcification and placement into the reader (outside time).
Liang et al. Thrombosis Journal 2013, 11:12 Page 4 of 9
http://www.thrombosisjournal.com/content/11/1/12random error (e.g., row C lower than row D on Figure 2C)
and a systematic trend across different rows (reduction of
TPH from row A to row H). More importantly, highly
concentrated IVIG sample was less affected by the system-
atic row drift than highly diluted samples, as evidenced by
different slopes of respective TPHs (compare blue and
red lines on Figure 2D). Therefore, a procoagulant activity
calibration curve rather than normalization on a single
concentration of row control should be used for correction
of row artifacts.
Row effects for FXIa on different microplate
reader instruments
Microplate reader models differ in the patterns of
microplate movement, vibration rate and flow of heated
air inside the instrument, possibly changing the kineticsof coagulation in microwells, e.g., “edge” artifacts of vari-
able intensity. However, we found that two different
microplate readers produced similar row-to-row artifacts
when the same set of samples was tested in parallel
(Figure 3C). Note that these experiments utilized titra-
tion of FXIa, a coagulation protein previously identi-
fied as the primary thrombogenic substance in IVIG
products [14,15,18]. Procoagulant IVIG lot and puri-
fied FXIa produced similar dose responses in the TGT
(compare Figures 2B and 3B) and similar row-to-row
drifts (Figures 2D and 3C).
Correction of row-to-row artifacts with symmetrical
duplicate well averaging
Systematic analysis of analytical and preanalytical vari-
ables revealed that the time period from recalcification
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Figure 3 Similar row artifacts observed on two different microplate reader instruments. A. 96 well microplate diagram showing
row-to-row location of FXIa. Blue and red colors on this and other panels denote 37 and 1.2 pM of FXIa (sample concentration before it was
added to plasma). B. Thrombin generation profiles in FXIDP. Data from row B. C. Effect of row location on the TPH measured in two parallel TGT
assays on two microplate reader instruments. D. Averaging data from symmetrical rows A/H, B/G, C/F and D/E corrects the row trend artifact.
Means ± S.D. (n = 2 wells).
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the plate reader (outside time) correlates with the TPH
(e.g., see Figures 1C, 2D and 3C). Therefore, averaging
identical samples on opposite rows, e.g., rows C + F
and rows B + G (see white and green connected circles
on Figure 3A diagram), compensated for the row drift
at all FXIa concentrations (Figure 3D). In practice,
quantitative assessment of procoagulant samples against
the activity control would require serial dilutions of sam-
ples and controls to be arranged vertically and symmetric-
ally with respect to the center of the microplate, as shown
on Figure 4A diagram. To confirm utility of this approach,the IVIG sample dilutions from the experiment shown on
Figure 2 were retested using the symmetrical vertical strip
plot design (Figure 4A), resulting in correction of row arti-
facts (Figure 4B).
Row effects in a commercial TGT
Since row drifts were proportional to recalcification times,
fast recalcification may improve row artifacts. Consistent
with this prediction, we found less pronounced location-
dependent effects in a commercially available CAT®
variant of the TGT assay which is equipped with the auto-
mated calcium chloride dispenser. Separate experiments
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Figure 4 Symmetrical strip-plot layout for duplicate wells corrects for row artifacts. A. Symmetrical plate layout design in which duplicate
wells are positioned symmetrically with respect to the plate center. Blue and red colors on this and other panels denote 1.6- and 16.8-fold
dilutions, respectively. Colored circles denote three examples of duplicate wells: B1 and G12, H1 and A12, and D2 and E11. B. Correction of
row-to-row location effects in samples arranged symmetrically. The conditions of the experiment are similar to shown on Figure 2 with the
exception of a different layout design. Means ± S.D. (n = 2 wells).
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CAT assays (e.g., order of substrate addition, volume of
plasma, TF concentration) could not explain the different
degree of row effects (data not shown). To understand the
difference between adjacent and symmetrical averaging of
duplicate wells, we placed identical FXIa titrations along
every column and the direction of the titration along the
column was symmetrical with respect to the center of the
plate (refer to Figure 5A). This order is roughly con-
sistent with the left-to-right direction of column-wise
recalcification order by the automated CAT instru-
ment. Blue lines on Figure 5B demonstrate column
drifts when adjacent duplicate wells containing same
FXIa concentrations are averaged (examples of adja-
cent wells are marked with blue circles on Figure 5A).
The drifts were eliminated when symmetrically ar-
ranged wells were averaged (Figure 5A, orange circles,
and Figure 5B, orange lines). Furthermore, symmetrical
averaging of wells produced overlapping dose-response
curves for FXIa-dependent TPH (Figure 5D), while adja-
cent averaging produced shifted dose-response curves
(Figure 5C).
Importance of row effect correction for
quantitative bioassay
To estimate the potential bias in a FXIa bioassay [15]
produced by the row and column artifacts, we utilized
the data from the CAT experiment (Figure 5) that dem-
onstrated the lowest systematic drift of all experiments.
The data from the first column or averaged data from
symmetrical columns 1 and 12 was used as a calibration
curve, as shown on Figure 6A and B. Although the dif-
ference between fitted curves was seemingly small, the
activity of FXIa dilutions on columns from left to rightexperienced progressive reduction up to 30% (Figure 6C,
black line). In contrast, symmetrical averaging elimi-
nated this trend completely (gray line).
Discussion
The clinical laboratory version of the TGT is usually
intended for comparison of coagulation potentials of pa-
tient and healthy donor plasma samples [2,3] or patient-
specific evaluation of the procoagulant and anti-coagulant
effects of existing and investigational treatments [4,5].
Consequently, prior research on TGT assay development
largely focused on preanalytical conditions and proper
calibration of assay in units of thrombin activity. Improved
quality of collected blood plasma samples, control of
plasma temperature as well as internal thrombin calibra-
tion or normalization on standard plasma sample were
shown to improve assay performance.
Evaluation of drug efficacy and quality, unlike clinical
applications, may be less sensitive to preanalytical condi-
tions because several drug preparations are compared
with each other on the same microplate using a single
sample of plasma. However, quantitative assessment of
the difference between drug preparations usually re-
quires comparison of different drug doses. Ideally, a bio-
assay is employed in which comparison to a standard
drug preparation employs a calibration curve or a paral-
lel line assay. Therefore, biotechnology applications re-
quire additional TGT qualification to ensure consistent
low limit of detection, linear dose-response range and
parallelism of tested and standard drugs.
Randomization of samples is an effective solution to
correct location effects in high throughput analytical as-
says, but complete randomization of sample layout on
the microtiter plate is prone to procedural errors [20]. A
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Figure 5 Location effects in the commercial thrombin generation assay (CAT). A. Symmetrical plate layout design in which FXIa titration
was repeated on columns 1 through 6, and, in reversed direction of sample dilutions, on columns 7 through 12. Colored circles denote two
algorithms of duplicate well averaging: orange circles demonstrate symmetrically positioned duplicate wells; blue circles demonstrated adjacent
position of duplicate wells. “TC” denotes thrombin calibrator wells. B. Adjacent averaging (blue lines) reveals column drifts in TPH while
symmetrical averaging of duplicate samples corrects this trend (orange lines). Means ± S.D. (n = 2 wells). C. Effect of column location on the FXIa
dose - TPH response curves in the case of adjacent averaging. D. Symmetrically averaged columns overlap indicating corrected location artifacts.
Means ± S.D. (n = 2 wells).
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samples are assigned to random columns and serial dilu-
tions of each sample to one column [20]. However, in a
typical TGT experiment, more samples are tested than
there are columns on a plate, and the number of serial
dilutions is smaller than there are rows. Since all coagu-
lation samples are tested at least in duplicates, we
propose to use a symmetrical design in which duplicates
are positioned symmetrically with respect to the center
of the plate. When applied to IVIG-TGT, this approach
corrects the row-to-row drift and is easy to implement:
(a) prior to addition to plasma, double volumes of IVIG
samples are arranged in columns 1 through 6 (half of
the plate), each sample in a single well, dilutions ar-
ranged vertically, (b) plasma is mixed with other re-
quired reagents (e.g., lipids) and transferred to cover all
96 wells of another plate, (c) IVIG samples are trans-
ferred to columns 1 through 6 of the plasma plate, (d)
the plasma plate is then rotated 180° degrees, and (e)
step c is repeated.
While we encountered location errors during drug
screening studies, these findings may be even more im-
portant for other TGT applications, e.g., use of TGT for
diagnosis and treatment of patients [5]. Sensitivity ofcoagulation assays to pre-analytical conditions has been
known for decades yet the causes of TGT variability
have only recently been investigated [19], but location
artifacts were not discussed in the literature. Location ef-
fect can be introduced in various ways. We found that if
a coagulation enzyme, e.g., FXIa or FVIIa, is added
manually to multiple wells on a microtiter plate, a well-
to-well drift appears due to the different durations of
contact between the enzyme and plasma inhibitors. A
similar effect may be observed if TF or contact activator
is added manually before recalicification. In our experi-
ence, long exposure of plasma to fluorogenic substrate
prior to recalcification also decreases the TGT response.
Edge effects can be caused by uneven heating of
microplate inside the reader and artifacts of liquid dis-
penser. It should be noted that internal normalization
on the thrombin-α2macroglobulin activity calibrator
(e.g., as proposed by Hemker et al. [21]) is not helpful
here because the thrombin calibrator only corrects for
fluorogenic signal-related inaccuracies and fails to cor-
rect for biological and pipetting variables [22]. All lo-
cation effects may be corrected with the use of the
strip-plot sample design. Specifically, when edge arti-






















 Individual columns                      
 Column #













































A Fitted standard curve
Figure 6 Biases introduced by location artifacts in the commercial CAT instrument. A. Plate layout demonstrating two locations of
calibrations curves, column 1 vs. averaged symmetrical columns 1 + 12, used for bioassay analysis in this figure. “TC” denotes thrombin calibrator
wells. B. Calibration curves from column 1 (filled symbols) and averaged columns 1 + 12 (open symbols) fitted using polynomial equations
(red lines). Means ± S.D. (n = 2 wells). C. Calculated FXIa concentrations obtained for either individual columns 1 through 12 against calibration
curve from column 1 (filled symbols) or for averaged symmetrical columns 1 + 12, 2 + 11, etc. against the calibration curve from columns 1 + 12.
The activities of FXIa samples were calculated under the assumption that each column contained a single sample that was serially diluted,
starting with the highest “neat” sample in the first well of the respective column, followed with 2.5 dilutions for wells 2 through 7 (well 8 was
“blank” buffer control). In the bioassay, TPH of each well in the column series was compared with the calibration curve (Figure 6B), and resultant
FXIa concentration was multiplied by the respective dilution factor. Thereafter, the FXIa data from the first 6 wells were averaged, and S.D. was
calculated. The highest diluted sample in well 7 was ignored because it was too close to the limit of assay detection.
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based TGT experiments.
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